文献速递皮肤肿瘤银屑病与炎症性皮肤病

再次移植实体器官受者皮肤癌风险及风险分层

Beyond the first graft: skin cancer risk and risk stratification in retransplanted solid organ recipients.
PubMed 文献 · Br J Dermatol · 2026-01-01

再次移植的实体器官移植受者(R-SOTR)因需更强免疫抑制而皮肤癌风险更高,尤其皮肤鳞状细胞癌(cSCC)。本文通过叙述性综述(2000年1月至2026年2月文献)提出基于既往皮肤癌史的五层风险分层框架,旨在辅助个体化评估与随访,而非规定监测间隔。

要点

  • 再次移植受者皮肤癌风险更高,尤其侵袭性cSCC。
  • 现有风险分层工具未纳入再次移植状态或累积免疫抑制负荷。
  • 提出五层框架:无皮肤癌史、单发非侵袭性cSCC、多发cSCC、组织学侵袭性cSCC、转移性cSCC。

核心结论

  • 再次移植是移植后皮肤癌结局的风险指标,需个体化皮肤癌风险评估。
  • 提出基于既往皮肤癌史的五层风险分层框架,用于识别需更密切皮肤科随访的患者。

研究设计与样本

  • 叙述性综述,检索2000年1月至2026年2月发表的原始研究、指南和共识声明。

主要发现

  • 肾脏和心脏登记数据显示再次移植是移植后皮肤癌结局的风险指标。
  • 唯一报告再次移植后皮肤结局的队列(高度选择的既往有cSCC的肾移植受者)显示再次移植后侵袭性cSCC发生率更高。
  • 移植受者发生cSCC的可能性高达一般人群的150倍,且肿瘤更具侵袭性。

关键数值与推荐

  • 框架将再次移植受者按既往皮肤癌史分为五类:无既往皮肤癌、既往单发非侵袭性cSCC、既往多发cSCC、既往组织学侵袭性cSCC、既往转移性cSCC。
  • 现有风险分层工具(如Skin and Ultraviolet Neoplasia Transplant Risk Assessment Calculator)未纳入再次移植状态或累积免疫抑制负荷。

临床怎么用

  • 框架用于支持个体化风险评估,识别可能需更密切皮肤科随访的患者,而非规定具体监测间隔。

局限性

  • 直接证据有限,框架基于有限证据提出。
  • 缺乏再次移植特异性的皮肤科监测指南。
  • 亟需前瞻性研究评估风险分层监测对皮肤癌结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Solid organ transplant recipients (SOTRs) face a markedly elevated risk of post-transplant skin cancer, particularly cutaneous squamous cell carcinoma (cSCC). This risk is driven by chronic immunosuppression, including the direct oncogenic effects of some immunosuppressive drugs, and cumulative carcinogenic risk factors including ultraviolet radiation exposure. Retransplanted SOTRs (R-SOTRs) represent a growing yet under-recognized subgroup, carrying additional vulnerability as the second or third transplant will often require more profound immunosuppression. Despite this, no retransplant-specific dermatological surveillance guidelines currently exist. Risk-stratification tools, including the Skin and Ultraviolet Neoplasia Transplant Risk Assessment Calculator, do not incorporate retransplantation status or cumulative immunosuppressive burden. Given the plausibly amplified risk profile of this population, a conceptual framework for skin cancer risk stratification in the context of retransplantation remains an unmet clinical need. To address this, we conducted a narrative review of studies published between January 2000 and February 2026, synthesizing primary studies alongside relevant guidelines and consensus statements. Kidney and heart registry data identify retransplantation as a risk indicator for post-transplant skin cancer outcomes, while the only cohort that reported cutaneous outcomes after retransplantation, comprising highly selected kidney recipients with prior cSCC, demonstrated higher rates of aggressive cSCC after retransplantation. Therefore, we propose a conceptual framework stratifying R-SOTRs into five risk categories according to prior skin cancer history, acknowledging the limited direct evidence currently available: no prior skin cancer, prior single nonaggressive cSCC, prior multiple cSCC, prior histologically aggressive cSCC and prior metastatic cSCC. This framework is intended to support individualized risk assessment and to identify patients likely to warrant closer dermatological follow-up, rather than to prescribe specific surveillance intervals. Prospective studies evaluating the impact of risk-stratified surveillance on skin cancer outcomes in this population are urgently needed. People who have undergone an organ transplant must take medications for the rest of their lives. These medicines stop the body from rejecting the new organ. They suppress the immune system, which greatly increases the risk of skin cancer. The risk of cutaneous squamous cell carcinoma is particularly increased. In fact, transplant recipients are up to 150 times more likely to develop this type of skin cancer than the general population. Moreover, the tumours tend to be more aggressive in these patients. Some transplant recipients can lose their transplanted organ and need a further transplant. This process is called retransplantation. These people are especially vulnerable. Each transplant requires another round of immune-suppressing medication. Higher dosages are often required. Despite this, no specific skin cancer-monitoring guidelines exist for patients who have undergone retransplantation. We wanted to understand the skin cancer risk in retransplanted organ recipients. Therefore, we conducted a review of studies published between 2000 and 2026. We also assessed what monitoring strategies are currently available. Our research team is based across Europe. The team worked within the Skin Care in Organ Transplant Patients Europe Network. This is a pan-European collaboration in transplant dermatology. We found that retransplantation is consistently associated with higher skin cancer rates and worse survival outcomes. This was true across different organ types. People who had skin cancer before their second transplant had a particularly high risk of aggressive disease. Based on this evidence, we propose a five-tier framework. It groups retransplanted organ recipients by their prior skin cancer history. This framework helps identify people who may benefit from closer skin monitoring. This ranges from those with no prior skin cancer through to those who have had aggressive or spreading skin cancer. The available evidence is still limited. Therefore, this framework is intended to guide clinical judgement and highlight who is at greater risk. It is not intended to set fixed monitoring schedules. We hope this framework helps clinicians protect this vulnerable and growing patient group. The framework could also serve as a foundation for future research and evidence-based guidelines.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Rünger A, Geusau A, Nägeli M, et al. Beyond the first graft: skin cancer risk and risk stratification in retransplanted solid organ recipients. Br J Dermatol. 2026. PMID: 42455021. doi:10.1093/bjd/ljag286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。